Midface volumization and skin quality enhancement with a hyaluronic acid-polynucleotide hybrid filler: a 24-week prospective open-label study [0.03%]
一种透明质酸-多核苷酸混合填充剂的中面部容量增加和皮肤质量改善：一项为期24周的前瞻性开放标签研究
So Young Lee,Choon Shik Youn,Kui Young Park
So Young Lee
Background: Facial aging is characterized by midface volume loss from structural and dermal atrophy. Objectives: To evaluate the effica...
Safety, tolerability, and pharmacokinetics of CG2001 in Chinese adult male subjects with androgenetic alopecia: a randomized, double-blind, placebo-controlled, single- and multi-doses, phase 1 clinical study [0.03%]
CG2001治疗雄激素性脱发受试者的安全性、耐受性和药代动力学：一项在中国成年男性中进行的随机、双盲、安慰剂对照及单次和多次给药剂量的Ⅰ期临床试验
Yanting Li,Baohui Yu,Suping Niu et al.
Yanting Li et al.
Objectives: Compared with placebo, this phase I study evaluated the safety, tolerability, and pharmacokinetics of CG2001, a novel isopropyl alcohol-free minoxidil-finasteride combination topical foam, in Chinese males wit...
Ivarmacitinib in patients with moderate to severe atopic dermatitis stratified by baseline characteristics: a post-hoc analysis of a phase 3 clinical trial [0.03%]
依伏馬西替治療中至重度特應性皮炎的亞組分析：一項三期臨床試驗的事後分析
Chaoying Gu,Aijun Chen,Huibin Yin et al.
Chaoying Gu et al.
Background: Ivarmacitinib (SHR0302) is a novel and highly selective Janus kinase 1 inhibitor for treating moderate to severe atopic dermatitis (AD). Objec...
Risankizumab super responders in moderate-to-severe psoriasis: prevalence, predictors, and long-term maintenance in a multicenter, international, real-world cohort [0.03%]
利桑基珠单抗治疗中重度银屑病应答良好的患者：患病率、预测因素和长期维持剂量在多中心国际真实世界队列中的研究
Diego Orsini,Luca Potestio,Matteo Megna et al.
Diego Orsini et al.
Background/objectives: The concept of super responders (SRs) has gained increasing attention in psoriasis. However, evidence focusing exclusively on risankizumab remains limited. This multicenter, international, real-worl...
Observational Study
The Journal of dermatological treatment. 2026 Dec;37(1):2617770. DOI:10.1080/09546634.2026.2617770 2026
Long-term efficacy and tolerability of clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel for acne: pooled results from two 6-month studies [0.03%]
长期疗效和耐受性研究：克林霉素磷酸酯/阿达帕林/过氧化苯甲酰凝胶联合治疗痤疮患者长达6个月的研究结果
Zoe D Draelos,Hilary Baldwin,Julie C Harper et al.
Zoe D Draelos et al.
Aim: Given the chronic nature of acne, two 6-month studies were conducted to evaluate the long-term efficacy and tolerability of clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide (BPO) 3.1% gel (CAB)-the only ap...
Estimated cost savings and formulary coverage barriers in biosimilar adoption [0.03%]
生物类似药使用中的成本节省及药品形式报销障碍评估
Alina S Feng,I-Chun Lin,Christopher G Youn et al.
Alina S Feng et al.
Does ANA positivity affect treatment outcomes in vitiligo? A clinical evaluation of 308-nm excimer light therapy [0.03%]
抗核抗体阳性是否影响白癜风的治疗效果？一种308纳米准分子光疗的临床评估
Ning Han,Dechao Jia,Cheng Chen et al.
Ning Han et al.
Objectives: Vitiligo is an autoimmune skin disorder characterized by melanocyte destruction and frequently associated with autoantibodies such as antinuclear antibodies (ANA). However, the clinical relevance of ANA positi...
Oral finasteride use and sexual adverse events: signal detection from disproportionality analyses of data from the United States Food and Drug Administration Adverse Event Reporting System [0.03%]
口服非那雄胺的使用与性不良事件：来自美国食品药品监督管理局不良事件报告系统的 disproportionality 分析信号检测结果
Aditya K Gupta,Mesbah Talukder,Greg Williams et al.
Aditya K Gupta et al.
Background: Oral finasteride 1 milligram (1 mg) daily-which is a 5-alpha reductase inhibitor (5-ARI) approved by the Food and Drug Administration (FDA) for androgenetic alopecia-is linked to sexual adverse events (AEs). H...
Persistence of interleukin-17 and interleukin-23 inhibitors in patients with plaque psoriasis: a real-world study in Taiwan [0.03%]
台湾斑块型银屑病患者接受白细胞介素-17和白细胞介素-23抑制剂治疗的持久性：一项真实世界研究
Yu-Huei Huang,Youran Xu,Shu-Chen Chang et al.
Yu-Huei Huang et al.
Objectives: IL-17 inhibitors (IL-17i) and IL-23 inhibitors (IL-23i) are advanced treatments for moderate-to-severe plaque psoriasis. This study aimed to assess the persistence of IL-17i and IL-23i in patients with plaque ...